{"pmid":32160149,"title":"Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with 2019 Novel Coronavirus Disease, United States.","text":["Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with 2019 Novel Coronavirus Disease, United States.","The etiologic agent of an outbreak of pneumonia in Wuhan, China, was identified as severe acute respiratory syndrome coronavirus 2 in January 2020. A patient in the United States was given a diagnosis of infection with this virus by the state of Washington and the US Centers for Disease Control and Prevention on January 20, 2020. We isolated virus from nasopharyngeal and oropharyngeal specimens from this patient and characterized the viral sequence, replication properties, and cell culture tropism. We found that the virus replicates to high titer in Vero-CCL81 cells and Vero E6 cells in the absence of trypsin. We also deposited the virus into 2 virus repositories, making it broadly available to the public health and research communities. We hope that open access to this reagent will expedite development of medical countermeasures.","Emerg Infect Dis","Harcourt, Jennifer","Tamin, Azaibi","Lu, Xiaoyan","Kamili, Shifaq","Sakthivel, Senthil K","Murray, Janna","Queen, Krista","Tao, Ying","Paden, Clinton R","Zhang, Jing","Li, Yan","Uehara, Anna","Wang, Haibin","Goldsmith, Cynthia","Bullock, Hannah A","Wang, Lijuan","Whitaker, Brett","Lynch, Brian","Gautam, Rashi","Schindewolf, Craig","Lokugamage, Kumari G","Scharton, Dionna","Plante, Jessica A","Mirchandani, Divya","Widen, Steven G","Narayanan, Krishna","Makino, Shinji","Ksiazek, Thomas G","Plante, Kenneth S","Weaver, Scott C","Lindstrom, Stephen","Tong, Suxiang","Menachery, Vineet D","Thornburg, Natalie J","32160149"],"abstract":["The etiologic agent of an outbreak of pneumonia in Wuhan, China, was identified as severe acute respiratory syndrome coronavirus 2 in January 2020. A patient in the United States was given a diagnosis of infection with this virus by the state of Washington and the US Centers for Disease Control and Prevention on January 20, 2020. We isolated virus from nasopharyngeal and oropharyngeal specimens from this patient and characterized the viral sequence, replication properties, and cell culture tropism. We found that the virus replicates to high titer in Vero-CCL81 cells and Vero E6 cells in the absence of trypsin. We also deposited the virus into 2 virus repositories, making it broadly available to the public health and research communities. We hope that open access to this reagent will expedite development of medical countermeasures."],"journal":"Emerg Infect Dis","authors":["Harcourt, Jennifer","Tamin, Azaibi","Lu, Xiaoyan","Kamili, Shifaq","Sakthivel, Senthil K","Murray, Janna","Queen, Krista","Tao, Ying","Paden, Clinton R","Zhang, Jing","Li, Yan","Uehara, Anna","Wang, Haibin","Goldsmith, Cynthia","Bullock, Hannah A","Wang, Lijuan","Whitaker, Brett","Lynch, Brian","Gautam, Rashi","Schindewolf, Craig","Lokugamage, Kumari G","Scharton, Dionna","Plante, Jessica A","Mirchandani, Divya","Widen, Steven G","Narayanan, Krishna","Makino, Shinji","Ksiazek, Thomas G","Plante, Kenneth S","Weaver, Scott C","Lindstrom, Stephen","Tong, Suxiang","Menachery, Vineet D","Thornburg, Natalie J"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32160149","week":"202011|Mar 09 - Mar 15","doi":"10.3201/eid2606.200516","keywords":["2019 novel coronavirus disease","COVID-19","PCR","SARS-CoV-2","United States","characterization","coronavirus","isolation","respiratory infections","severe acute respiratory syndrome coronavirus 2","viruses","zoonoses"],"source":"PubMed","locations":["Washington","United States","Wuhan","China"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1661359647848660992,"score":6.7365713,"similar":[{"pmid":32149036,"pmcid":"PMC7045880","title":"Identification of Coronavirus Isolated from a Patient in Korea with COVID-19.","text":["Identification of Coronavirus Isolated from a Patient in Korea with COVID-19.","Objectives: Following reports of patients with unexplained pneumonia at the end of December 2019 in Wuhan, China, the causative agent was identified as coronavirus (SARS-CoV-2), and the 2019 novel coronavirus disease was named COVID-19 by the World Health Organization. Putative patients with COVID-19 have been identified in South Korea, and attempts have been made to isolate the pathogen from these patients. Methods: Upper and lower respiratory tract secretion samples from putative patients with COVID-19 were inoculated onto cells to isolate the virus. Full genome sequencing and electron microscopy were used to identify the virus. Results: The virus replicated in Vero cells and cytopathic effects were observed. Full genome sequencing showed that the virus genome exhibited sequence homology of more than 99.9% with SARS-CoV-2 which was isolated from patients from other countries, for instance China. Sequence homology of SARS-CoV-2 with SARS-CoV, and MERS-CoV was 77.5% and 50%, respectively. Coronavirus-specific morphology was observed by electron microscopy in virus-infected Vero cells. Conclusion: SARS-CoV-2 was isolated from putative patients with unexplained pneumonia and intermittent coughing and fever. The isolated virus was named BetaCoV/Korea/KCDC03/2020.","Osong Public Health Res Perspect","Kim, Jeong-Min","Chung, Yoon-Seok","Jo, Hye Jun","Lee, Nam-Joo","Kim, Mi Seon","Woo, Sang Hee","Park, Sehee","Kim, Jee Woong","Kim, Heui Man","Han, Myung-Guk","32149036"],"abstract":["Objectives: Following reports of patients with unexplained pneumonia at the end of December 2019 in Wuhan, China, the causative agent was identified as coronavirus (SARS-CoV-2), and the 2019 novel coronavirus disease was named COVID-19 by the World Health Organization. Putative patients with COVID-19 have been identified in South Korea, and attempts have been made to isolate the pathogen from these patients. Methods: Upper and lower respiratory tract secretion samples from putative patients with COVID-19 were inoculated onto cells to isolate the virus. Full genome sequencing and electron microscopy were used to identify the virus. Results: The virus replicated in Vero cells and cytopathic effects were observed. Full genome sequencing showed that the virus genome exhibited sequence homology of more than 99.9% with SARS-CoV-2 which was isolated from patients from other countries, for instance China. Sequence homology of SARS-CoV-2 with SARS-CoV, and MERS-CoV was 77.5% and 50%, respectively. Coronavirus-specific morphology was observed by electron microscopy in virus-infected Vero cells. Conclusion: SARS-CoV-2 was isolated from putative patients with unexplained pneumonia and intermittent coughing and fever. The isolated virus was named BetaCoV/Korea/KCDC03/2020."],"journal":"Osong Public Health Res Perspect","authors":["Kim, Jeong-Min","Chung, Yoon-Seok","Jo, Hye Jun","Lee, Nam-Joo","Kim, Mi Seon","Woo, Sang Hee","Park, Sehee","Kim, Jee Woong","Kim, Heui Man","Han, Myung-Guk"],"date":"2020-03-10T11:00:00Z","year":2020,"_id":"32149036","week":"202011|Mar 09 - Mar 15","doi":"10.24171/j.phrp.2020.11.1.02","keywords":["COVID-19","SARS-CoV-2","coronavirus","isolation","pneumonia"],"source":"PubMed","locations":["Wuhan","South Korea","China"],"countries":["Korea, Republic of","China"],"countries_codes":["KOR|Korea, Republic of","CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1661359647799377920,"score":189.35402},{"pmid":32053579,"pmcid":"PMC7017962","title":"Persons Evaluated for 2019 Novel Coronavirus - United States, January 2020.","text":["Persons Evaluated for 2019 Novel Coronavirus - United States, January 2020.","In December 2019, a cluster of cases of pneumonia emerged in Wuhan City in central China's Hubei Province. Genetic sequencing of isolates obtained from patients with pneumonia identified a novel coronavirus (2019-nCoV) as the etiology (1). As of February 4, 2020, approximately 20,000 confirmed cases had been identified in China and an additional 159 confirmed cases in 23 other countries, including 11 in the United States (2,3). On January 17, CDC and the U.S. Department of Homeland Security's Customs and Border Protection began health screenings at U.S. airports to identify ill travelers returning from Wuhan City (4). CDC activated its Emergency Operations Center on January 21 and formalized a process for inquiries regarding persons suspected of having 2019-nCoV infection (2). As of January 31, 2020, CDC had responded to clinical inquiries from public health officials and health care providers to assist in evaluating approximately 650 persons thought to be at risk for 2019-nCoV infection. Guided by CDC criteria for the evaluation of persons under investigation (PUIs) (5), 210 symptomatic persons were tested for 2019-nCoV; among these persons, 148 (70%) had travel-related risk only, 42 (20%) had close contact with an ill laboratory-confirmed 2019-nCoV patient or PUI, and 18 (9%) had both travel- and contact-related risks. Eleven of these persons had laboratory-confirmed 2019-nCoV infection. Recognizing persons at risk for 2019-nCoV is critical to identifying cases and preventing further transmission. Health care providers should remain vigilant and adhere to recommended infection prevention and control practices when evaluating patients for possible 2019-nCoV infection (6). Providers should consult with their local and state health departments when assessing not only ill travelers from 2019-nCoV-affected countries but also ill persons who have been in close contact with patients with laboratory-confirmed 2019-nCoV infection in the United States.","MMWR Morb Mortal Wkly Rep","Bajema, Kristina L","Oster, Alexandra M","McGovern, Olivia L","Lindstrom, Stephen","Stenger, Mark R","Anderson, Tara C","Isenhour, Cheryl","Clarke, Kevin R","Evans, Mary E","Chu, Victoria T","Biggs, Holly M","Kirking, Hannah L","Gerber, Susan I","Hall, Aron J","Fry, Alicia M","Oliver, Sara E","32053579"],"abstract":["In December 2019, a cluster of cases of pneumonia emerged in Wuhan City in central China's Hubei Province. Genetic sequencing of isolates obtained from patients with pneumonia identified a novel coronavirus (2019-nCoV) as the etiology (1). As of February 4, 2020, approximately 20,000 confirmed cases had been identified in China and an additional 159 confirmed cases in 23 other countries, including 11 in the United States (2,3). On January 17, CDC and the U.S. Department of Homeland Security's Customs and Border Protection began health screenings at U.S. airports to identify ill travelers returning from Wuhan City (4). CDC activated its Emergency Operations Center on January 21 and formalized a process for inquiries regarding persons suspected of having 2019-nCoV infection (2). As of January 31, 2020, CDC had responded to clinical inquiries from public health officials and health care providers to assist in evaluating approximately 650 persons thought to be at risk for 2019-nCoV infection. Guided by CDC criteria for the evaluation of persons under investigation (PUIs) (5), 210 symptomatic persons were tested for 2019-nCoV; among these persons, 148 (70%) had travel-related risk only, 42 (20%) had close contact with an ill laboratory-confirmed 2019-nCoV patient or PUI, and 18 (9%) had both travel- and contact-related risks. Eleven of these persons had laboratory-confirmed 2019-nCoV infection. Recognizing persons at risk for 2019-nCoV is critical to identifying cases and preventing further transmission. Health care providers should remain vigilant and adhere to recommended infection prevention and control practices when evaluating patients for possible 2019-nCoV infection (6). Providers should consult with their local and state health departments when assessing not only ill travelers from 2019-nCoV-affected countries but also ill persons who have been in close contact with patients with laboratory-confirmed 2019-nCoV infection in the United States."],"journal":"MMWR Morb Mortal Wkly Rep","authors":["Bajema, Kristina L","Oster, Alexandra M","McGovern, Olivia L","Lindstrom, Stephen","Stenger, Mark R","Anderson, Tara C","Isenhour, Cheryl","Clarke, Kevin R","Evans, Mary E","Chu, Victoria T","Biggs, Holly M","Kirking, Hannah L","Gerber, Susan I","Hall, Aron J","Fry, Alicia M","Oliver, Sara E"],"date":"2020-02-14T11:00:00Z","year":2020,"_id":"32053579","week":"20207|Feb 10 - Feb 16","doi":"10.15585/mmwr.mm6906e1","source":"PubMed","locations":["United States","Hubei","USA","Wuhan","China"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1661359647250972672,"score":128.96663},{"pmid":32168465,"title":"Epidemiology of 2019 Novel Coronavirus Disease-19 in Gansu Province, China, 2020.","text":["Epidemiology of 2019 Novel Coronavirus Disease-19 in Gansu Province, China, 2020.","To determine the epidemiology of 2019 novel coronavirus disease (COVID-19) in a remote region of China, far from Wuhan, we analyzed the epidemiology of COVID-19 in Gansu Province. From January 23 through February 3, 2020, a total of 35 (64.8%) of 54 reported cases were imported from COVID-19-epidemic areas. Characteristics that differed significantly during the first and second waves of illness in Gansu Province were mean patient age, occupation, having visited epidemic areas, and mode of transportation. Time from infection to illness onset for family clusters was shorter in Gansu Province than in Wuhan, consistent with shortened durations from onset to first medical visit or hospitalization. Spatial distribution pattern analysis indicated hot spots and spatial outliers in Gansu Province. As a result of adequate interventions, transmission of the COVID-19 virus in Gansu Province is decreasing.","Emerg Infect Dis","Fan, Jingchun","Liu, Xiaodong","Pan, Weimin","Douglas, Mark W","Bao, Shisan","32168465"],"abstract":["To determine the epidemiology of 2019 novel coronavirus disease (COVID-19) in a remote region of China, far from Wuhan, we analyzed the epidemiology of COVID-19 in Gansu Province. From January 23 through February 3, 2020, a total of 35 (64.8%) of 54 reported cases were imported from COVID-19-epidemic areas. Characteristics that differed significantly during the first and second waves of illness in Gansu Province were mean patient age, occupation, having visited epidemic areas, and mode of transportation. Time from infection to illness onset for family clusters was shorter in Gansu Province than in Wuhan, consistent with shortened durations from onset to first medical visit or hospitalization. Spatial distribution pattern analysis indicated hot spots and spatial outliers in Gansu Province. As a result of adequate interventions, transmission of the COVID-19 virus in Gansu Province is decreasing."],"journal":"Emerg Infect Dis","authors":["Fan, Jingchun","Liu, Xiaodong","Pan, Weimin","Douglas, Mark W","Bao, Shisan"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32168465","week":"202011|Mar 09 - Mar 15","doi":"10.3201/eid2606.200251","keywords":["2019 novel coronavirus disease","COVID-19","China","Gansu Province","SARS-CoV-2","Wuhan","coronavirus","outbreaks","respiratory infections","severe acute respiratory syndrome coronavirus 2","viruses","zoonoses"],"source":"PubMed","locations":["Gansu","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1661359647931498496,"score":124.27236},{"pmid":32106216,"title":"Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020.","text":["Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020.","An outbreak of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) began in Wuhan, Hubei Province, China in December 2019, and has spread throughout China and to 31 other countries and territories, including the United States (1). As of February 23, 2020, there were 76,936 reported cases in mainland China and 1,875 cases in locations outside mainland China (1). There have been 2,462 associated deaths worldwide; no deaths have been reported in the United States. Fourteen cases have been diagnosed in the United States, and an additional 39 cases have occurred among repatriated persons from high-risk settings, for a current total of 53 cases within the United States. This report summarizes the aggressive measures (2,3) that CDC, state and local health departments, multiple other federal agencies, and other partners are implementing to slow and try to contain transmission of COVID-19 in the United States. These measures require the identification of cases and contacts of persons with COVID-19 in the United States and the recommended assessment, monitoring, and care of travelers arriving from areas with substantial COVID-19 transmission. Although these measures might not prevent widespread transmission of the virus in the United States, they are being implemented to 1) slow the spread of illness; 2) provide time to better prepare state and local health departments, health care systems, businesses, educational organizations, and the general public in the event that widespread transmission occurs; and 3) better characterize COVID-19 to guide public health recommendations and the development and deployment of medical countermeasures, including diagnostics, therapeutics, and vaccines. U.S. public health authorities are monitoring the situation closely, and CDC is coordinating efforts with the World Health Organization (WHO) and other global partners. Interim guidance is available at https://www.cdc.gov/coronavirus/index.html. As more is learned about this novel virus and this outbreak, CDC will rapidly incorporate new knowledge into guidance for action by CDC, state and local health departments, health care providers, and communities.","MMWR Morb Mortal Wkly Rep","Jernigan, Daniel B","32106216"],"abstract":["An outbreak of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) began in Wuhan, Hubei Province, China in December 2019, and has spread throughout China and to 31 other countries and territories, including the United States (1). As of February 23, 2020, there were 76,936 reported cases in mainland China and 1,875 cases in locations outside mainland China (1). There have been 2,462 associated deaths worldwide; no deaths have been reported in the United States. Fourteen cases have been diagnosed in the United States, and an additional 39 cases have occurred among repatriated persons from high-risk settings, for a current total of 53 cases within the United States. This report summarizes the aggressive measures (2,3) that CDC, state and local health departments, multiple other federal agencies, and other partners are implementing to slow and try to contain transmission of COVID-19 in the United States. These measures require the identification of cases and contacts of persons with COVID-19 in the United States and the recommended assessment, monitoring, and care of travelers arriving from areas with substantial COVID-19 transmission. Although these measures might not prevent widespread transmission of the virus in the United States, they are being implemented to 1) slow the spread of illness; 2) provide time to better prepare state and local health departments, health care systems, businesses, educational organizations, and the general public in the event that widespread transmission occurs; and 3) better characterize COVID-19 to guide public health recommendations and the development and deployment of medical countermeasures, including diagnostics, therapeutics, and vaccines. U.S. public health authorities are monitoring the situation closely, and CDC is coordinating efforts with the World Health Organization (WHO) and other global partners. Interim guidance is available at https://www.cdc.gov/coronavirus/index.html. As more is learned about this novel virus and this outbreak, CDC will rapidly incorporate new knowledge into guidance for action by CDC, state and local health departments, health care providers, and communities."],"journal":"MMWR Morb Mortal Wkly Rep","authors":["Jernigan, Daniel B"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32106216","week":"20209|Feb 24 - Mar 01","doi":"10.15585/mmwr.mm6908e1","source":"PubMed","locations":["United States","Hubei","USA","Wuhan","China"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["General Info"],"weight":1,"_version_":1661359647525699584,"score":122.14353},{"pmid":32160148,"title":"Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China.","text":["Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China.","We report co-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A virus in a patient with pneumonia in China. The case highlights possible co-detection of known respiratory viruses. We noted low sensitivity of upper respiratory specimens for SARS-CoV-2, which could further complicate recognition of the full extent of disease.","Emerg Infect Dis","Wu, Xiaojing","Cai, Ying","Huang, Xu","Yu, Xin","Zhao, Li","Wang, Fan","Li, Quanguo","Gu, Sichao","Xu, Teng","Li, Yongjun","Lu, Binghuai","Zhan, Qingyuan","32160148"],"abstract":["We report co-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A virus in a patient with pneumonia in China. The case highlights possible co-detection of known respiratory viruses. We noted low sensitivity of upper respiratory specimens for SARS-CoV-2, which could further complicate recognition of the full extent of disease."],"journal":"Emerg Infect Dis","authors":["Wu, Xiaojing","Cai, Ying","Huang, Xu","Yu, Xin","Zhao, Li","Wang, Fan","Li, Quanguo","Gu, Sichao","Xu, Teng","Li, Yongjun","Lu, Binghuai","Zhan, Qingyuan"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32160148","week":"202011|Mar 09 - Mar 15","doi":"10.3201/eid2606.200299","keywords":["2019 novel coronavirus disease","COVID-19","China","SARS-CoV-2","co-detection","co-infection","influenza","influenza A","pneumonia","severe acute respiratory syndrome coronavirus 2","viruses","zoonoses"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1661359647858098177,"score":116.2229}]}